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A Monte Carlo study on the feasibility of real-time in vivo source tracking during 
ultrasound based HDR prostate brachytherapy treatments 
Abstract 
Purpose 
This study aims to assess the accuracy of in-vivo source tracking during real-time trans-rectal ultrasound 
(TRUS) based high dose rate (HDR) prostate brachytherapy (pBT) through Monte Carlo simulations of 
multiple HDR pBT treatments with a two-dimensional (2D) diode array, the Magic Plate 900 (MP900), 
embedded below the patient in a carbon-fibre couch. 
Method 
Monte Carlo simulations of source positions representing three separate real-time TRUS based HDR pBT 
treatments were performed using the Geant4 toolkit. For each source position, an Ir-192 source was 
simulated inside a voxelized patient geometry. Dose deposited from each source position to the MP900 
diodes was used to perform source tracking, and the MP900 calculated position compared to known 
source positions from the treatment plan. Thresholding techniques were implemented to improve source 
tracking accuracy with the TRUS probe present. 
Results 
The average three-dimensional source position reconstruction discrepancy was 11.9 ± 2.4 mm and 1.5 ± 
0.3 mm with and without the TRUS probe, respectively. Thresholding techniques improved the source 
position reconstruction discrepancy in the presence of the TRUS probe to 1.8 ± 0.4 mm. 
Conclusion 
Inclusion of the TRUS probe inside the patient negatively affects source tracking accuracy when using the 
MP900 diode array for HDR pBT verification. Modification of the source tracking algorithm using 
thresholding techniques improves source tracking in the presence of the TRUS probe, achieving similar 
accuracy as when the TRUS probe is not present. This study demonstrates that accurate in-vivo source 
tracking during real-time TRUS based HDR pBT is feasible using the Magic Plate system. 
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Purpose: This study aims to assess the accuracy of in-vivo source tracking during real-time trans-rectal 
ultrasound (TRUS) based high dose rate (HDR) prostate brachytherapy (pBT) through Monte Carlo 
simulations of multiple HDR pBT treatments with a two-dimensional (2D) diode array, the Magic Plate 
900 (MP900), embedded below the patient in a carbon-fibre couch.  
Method: Monte Carlo simulations of source positions representing three separate real-time TRUS 
based HDR pBT treatments were performed using the Geant4 toolkit. For each source position, an Ir-
192 source was simulated inside a voxelized patient geometry. Dose deposited from each source 
position to the MP900 diodes was used to perform source tracking, and the MP900 calculated position 
compared to known source positions from the treatment plan. Thresholding techniques were 
implemented to improve source tracking accuracy with the TRUS probe present.   
Results: The average three-dimensional source position reconstruction discrepancy was 11.9 ± 2.4 mm 
and 1.5 ±0.3 mm with and without the TRUS probe, respectively. Thresholding techniques improved 
the source position reconstruction discrepancy in the presence of the TRUS probe to 1.8±0.4 mm. 
Conclusion: Inclusion of the TRUS probe inside the patient negatively affects source tracking accuracy 
when using the MP900 diode array for HDR pBT verification. Modification of the source tracking 
algorithm using thresholding techniques improves source tracking in the presence of the TRUS probe, 
achieving similar accuracy as when the TRUS probe is not present. This study demonstrates that 
accurate in-vivo source tracking during real-time TRUS based HDR pBT is feasible using the Magic 
Plate system. 








High dose rate (HDR) prostate brachytherapy (pBT) treatments are widely practiced in the 
radiation oncology community, most commonly in combination with external beam radiotherapy 
(EBRT) in the form of a boost. There have been a number of recent studies showing improved quality 
of life outcome for combined EBRT and HDR brachytherapy compared with EBRT alone [1-3]. 
Furthermore, there have been several studies that reported favourable results using HDR brachytherapy 
as a monotherapy [4, 5]. 
HDR pBT treatment plans are traditionally performed with the use of a post-operative CT scan. 
The major drawback of this technique is that it necessitates movement of the patient off the operating 
table and out of the dorsal lithotomy position. Multiple studies have reported that movement of the 
patient in this manor may increase the risk of catheter displacement in the inferior direction, relative to 
the prostate, in the time between CT scanning and treatment [6, 7]. The use of transrectal ultrasound 
(TRUS) for treatment planning [8] has been shown to reduce the magnitude of these shifts, as well as 
improve visibility of the prostate and organs at risk (OARs) [9]. Modern brachytherapy treatment 
planning systems (BTPS) are able to use the ultrasound echoes of the implanted catheters for the 
definition of the catheter position within the patient, allowing for ‘real-time’ HDR pBT treatment 
planning [9]. Correct identification of catheter positions on these images however can be difficult, and 
there remains a need for comprehensive pre-treatment and/or in-vivo quality assurance (QA) [10-12].  
Source tracking of dwell positions during HDR pBT treatments based on electronic portal 
imaging devices (EPIDs) have been performed previously [13-16]. However, when used for HDR 
brachytherapy source tracking, these EPID based devices are required to operate using low frame rates 
due to poor signal to noise ratios, and when compounded with their inherently slow read out electronics, 
loss of data for short dwell times can occur [14]. Furthermore, none of these studies have applied source 
position identification to TRUS based HDR pBT, where the presence of the TRUS probe is expected to 
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attenuate the signal collected by the device significantly, negatively affecting the source tracking 
accuracy. 
The aim of this study is to determine the feasibility of using a 2D diode array, the ‘Magic Plate 
900’ (MP900), developed at the Centre for Medical Radiation Physics (CMRP), University of 
Wollongong (UoW), for in-vivo source tracking during TRUS based HDR pBT. The presence of the 
TRUS probe was also simulated to evaluate its effect to the source position detection. The source 
tracking algorithm employed in this study utilizes the relative signal of each of the diodes in the array 
to perform a distance calculation from the HDR source to each of the diodes in the array as input. The 
distance from the source to each of the diodes is used in an algorithm based on a nonlinear least squares 
fit method to localize the source in three dimensions. Further details of the algorithm are described in a 
previous study [17].  Studies performed with a previous version of the device, the ‘Magic Plate 121’ 
(MP121), in homogeneous phantom media (i.e., the presence of the TRUS probe was not modelled) 
have reported source localization accuracy of less than 1 mm [18-20] and timing resolution of 0.1 
seconds [18]. A previous Monte Carlo study of the MP121, showed that source tracking accuracy with 
the device embedded in a carbon fibre couch below a patient in the lithotomy position was achievable 
to within 2 mm for CT based HDR pBT [17].  
 
II. MATERIALS AND METHODS 
To assess the feasibility of source localization using the MP900 during TRUS based HDR pBT 
Monte Carlo simulations were performed using the Geant4 toolkit (v4.10.01)[21, 22]. During the 
simulations, the Flexisource Ir-192 source (Elekta Brachytherapy, Veenendaal, The Netherlands) was 
simulated inside a voxelized patient geometry, and the dose deposited within the sensitive volume of 
each detector in the couch embedded 30x30 diode array was determined. The simulated detector dose 
was then used to determine the distance of all detectors in the array to each of the simulated source 
positions, and the array predicted source positions determined using an iterative process. The effect of 
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the TRUS probe on source localization accuracy was ascertained by performing the simulations both 
with and without a TRUS probe present in the patient volume. 
II.A Ir-192 Flexisource 
The geometric model of the Flexisource used in the simulations was obtained from Granero et 
al.[23]. The Ir-192 core is modelled as a pure Iridium cylinder of length 3.5 mm and diameter 0.6 mm, 
it has a physical density of 22.42 g/cm3.  The active Ir-192 core is surrounded by a stainless-steel shell 
of length 4.6 mm, 0.85 mm outer diameter and inner diameter of 0.67 mm. This results in a shell 
thickness of 0.09 mm. The composition by weight of the stainless-steel shell is modelled as follows: Fe 
67.92%, Cr 19%, Ni 10%, Mn 2%, Si 1% and C 0.08% and the physical density is 7.999 g/cm3. A more 
detailed description and validation of the Flexisource model used in the simulations has been presented 
in a previous study [17]. 
II.BMagic Plate 900 2-D Diode Array 
The MP900 contains diodes mounted on a 0.6 mm Kapton substrate using the ‘edgeless-drop-
in’ technique (Figure 1), as described in a study by Petasecca et al.[24]. These diodes have an improved 
angular dependence (less than 2%) compared to those used in the previous design of this system, thereby 
simplifying the source reconstruction algorithm and improving source tracking accuracy. Furthermore, 
the diodes have a larger sensitive volume (higher sensitivity) to allow for enhanced signal to noise ratio 
at larger source-to-detector distance. The diodes are arranged in the Kapton carrier with a 7 mm pitch, 




Figure 1. Schematic of the MP900 and of the ‘edgeless’ diode design used source tracking simulations. 
All dimensions are in millimetres, image is not to scale. 
 
II.C Source Tracking Simulations 
The MP900 was modelled in the source tracking simulations using the Geant4 toolkit 
(v4.10.01)[21, 22]. The materials and geometry of the MP900 were constructed according to the 
description of the device in Section II.B, embedded inside a 120 mm thick carbon fibre couch, offset 5 
mm from its anterior surface. 
The model of the patient anatomy in the simulations was created by converting DICOM CT 
studysets from HDR pBT treatments. This was accomplished by initially converting the Hounsfield unit 
(HU) to a mass density values using a CT-density curve, and then converting from mass density to a 
material using a look up table [25-27]. The patient geometry in Geant4 is then created as a geometrical 
phantom consisting of an array of voxels containing the materials (and their compositions) determined 
from the HU [27]. The compositions and the densities of materials used in the simulations were obtained 
from the AAPM TG 186 Report [28]. The voxel size was set to 3x3x3 mm in this study. 
A TRUS probe was modelled inside the rectum of the voxelized patient geometries by utilizing 
a parallel geometry [29] to prevent overlapping volumes in the simulation, e.g. patient rectum and 
TRUS probe. These overlapping volumes cause errors in the tracking geometry of Geant4 simulations, 
leading to erroneous results. The TRUS probe was constructed based on the Endocavity Biplane 
Transducer Type 8848 produced by BK Medical. The model of the probe consisted of a 110x15x3 mm 
bar of brass (70% Copper, 30% Zinc, effective atomic number of 29.5), embedded inside a cylindrical 
Silicon casing (length 200 mm, diameter 22 mm). It should be noted that this model may not be 
representative of the true construction of the model 8848 probe, as details of the internal construction 
of the probe were unable to be obtained from the manufacturer. Therefore, a model was used that was 
intended to match the internal construction of the probe to the best of our knowledge and mimicked the 
construction of a probe analogue previously used in experiments by our institution [30].  Due to the 
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presence of the high atomic number materials inside the TRUS probe, it was expected that the TRUS 
probe would attenuate the signal collected by the MP900 significantly, negatively affecting the source 
tracking accuracy. Nevertheless, it’s important to note that the TRUS probe must remain in the rectum 
during patient irradiation in order to not modify the patient’s anatomy acquired for treatment planning 
[11]. 
Three complete HDR pBT treatments were simulated, consisting of three unique voxelized 
patient geometries. The source position locations from the treatment plans were re-created in the 
simulation geometry by using the three-dimensional source position locations obtained from the 
DICOM RTPlan files in the BTPS. As the patient geometry is also re-created in the simulations directly 
from the DICOM files, the position of the dwell locations relative to the patient anatomy in the 
simulations matches the BTPS. The characteristics of the three HDR pBT plans included in the study 
are outlined in Table I. The Flexisource model used in the simulations is described in Section II.A. The 
total energy deposited in the sensitive volume of each diode in the array was tallied during each 
simulation, which consisted of a total of 109 primary photons. The total energy deposited in the sensitive 
region of each diode was then divided by the mass of the sensitive volume to calculate the dose 
deposited. The source positions were then determined using the average diode dose as input into an 
source tracking algorithm [17, 18, 31] 
Table I – Characteristics of the three HDR pBT plans considered in the study. 
 Number of catheters Number of source positions 
Patient 1 19 154 
Patient 2 22 165 
Patient 3 18 153 
 
Finally, the MP900 determined source positions were compared to known source positions 
input into the simulations, which were obtained from the Oncentra Prostate (v4.2.3 Elekta 
Brachytherapy, Veenendaal, The Netherlands) BTPS. Source positions obtained from the BTPS 
coordinate system were converted to that of the MP900 coordinate system, as the position of the MP900 
relative to the patient geometry is known, fixed distance (the MP900 is rigidly embedded into the carbon 
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fibre couch below the patient) within the simulation geometry. The simulations were repeated with the 
TRUS probe replaced by tissue equivalent material in the patient geometry to examine the effect of the 
TRUS probe on the source tracking accuracy. 
To determine if the same accuracy of source tracking can be achieved both with and without 
the TRUS probe present, a thresholding technique was applied to the source tracking algorithm. Firstly, 
using the data from the simulations with the TRUS probe present, the maximum dose deposited in any 
diode was found for each source position. Secondly, for each source position in the three patient plans 
a threshold was applied, ranging from 50% - 90% of the maximum dose deposited in the array in 10% 
increments. Any diode with dose deposited below this threshold is ignored in the algorithm, and the 
optimal threshold level found that gave the best results as input into the source tracking algorithm when 
all source positions from the three treatment plans were considered. 
The average and maximum differences between MP900 predicted and actual source positions 
obtained with the TRUS probe, without the TRUS probe, and TRUS probe corrected (i.e. applying the 
optimal threshold), were computed and compared across all three patient volumes. Results without the 
TRUS probe and TRUS probe corrected were also compared by means of a Wilcoxian matched pair 
test. A p-value of <0.05 was considered significant. The test was performed using the R software (v3.5.1, 
The R Foundation for Statistical Computing, Vienna, Austria).   
 
III. RESULTS 
The average three-dimensional (3D) error vector of source tracking in the presence of the TRUS 
probe is shown in Table II for each direction within the three patient volumes, including: the patient 
left-right direction (X), superior-inferior direction (Y), and anterior-posterior direction (Z). The average 
3D error vector for all source positions in the three treatment plans was found to be 11.9 ± 2.4 mm (k = 
1). Figure 2.a) presents the distance calculation between each diode in the MP900 array from a source 
position in patient 1’s plan with the TRUS probe present. The colour scale represents the MP900 
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calculated distance (in mm) from each diode to the source. The effect of the TRUS probe can clearly be 
seen in the figure, resulting in an incorrect distance calculation for the diodes shadowed by the probe.   
a)  b)  
c)  
Figure 2.a) Distance calculation (mm) between the source and each diode in the MP900 from a source 
position in Patient 1 plan, affected by the presence of the TRUS probe.2.b) Distance calculation, without 
the TRUS probe present, 2.c) Distance calculation with 70% threshold applied, and diodes with red 
colours not included in the reconstruction algorithm. 
The simulations were then repeated without the TRUS probe present in the patient geometry 
examine the effect of the TRUS probe on the source tracking accuracy. Figure 2.b) presents the distance 
calculation between each diode in the MP900 array from a source position in patient 1’s plan without 
the TRUS probe present. The average 3D error vector for all source positions in the three treatment 
plans without the TRUS probe was 1.5 ± 0.3 mm (k = 1).  
Table II – Average difference between MP900 predicted and actual source positions in mm -

































X 6.1 ± 1.2 0.4 ± 0.4 0.6 ± 0.5 6.6 ± 1.4 0.4 ± 0.4 0.7 ± 0.6 5.8 ± 1.3 0.5 ± 0.4 0.7 ± 0.8 
Y 6.0 ± 1.4 0.4 ± 0.2 0.6 ± 0.5 6.3 ± 1.1 0.4 ± 0.2 0.6 ± 0.4 6.0 ± 1.5 0.5 ± 0.3 0.7 ± 0.7 
Z 8.1 ± 2.2 1.3 ± 0.2 1.6 ± 0.4 7.8 ± 2.7 1.3 ± 0.2 1.4 ± 0.4 8.4 ± 2.1 1.5 ± 0.5 1.5 ± 0.8 
3D 11.8 ± 2.4 1.4 ± 0.3 1.8 ± 0.6 12.0 ± 2.5 1.4 ± 0.3 1.7 ± 0.6 11.8 ± 2.3 1.7 ± 0.4 1.8 ± 0.7 
 
A thresholding technique was applied to the verification algorithm with the TRUS probe 
present. Figure 2.c) presents the distance calculation between each diode in the MP900 array from a 
source position in patient 1’s plan with the TRUS probe present and a 70% threshold applied. As can 
be seen from the figure, the threshold is able to eliminate the diodes shadowed by the TRUS probe as 
input into the verification algorithm. The effect of the application of different threshold levels in the 
source tracking algorithm is shown in Figure 3.  The optimal threshold level, averaged over all source 
positions in the three treatment plans was found to be 70%. By disregarding the signal of all diodes 
below 70% of the maximum signal of any diode in the array, an average source tracking accuracy of 
1.8±0.4 mm can be achieved in the clinically relevant condition of the presence of the TRUS probe 
inside the rectum. 
As can be seen in Table II, the variation in the 3D source tracking accuracy across the three 
patient volumes is less than 0.5 mm. This result highlights the excellent reproducibility of the MP900 
system and associated source tracking algorithm, regardless of variations in patient related tissue 
inhomogeneities. The maximum difference between MP900 predicted and actual source position was 
15.4 mm, 2.2 mm, and 3.0 mm, with the TRUS probe, without the TRUS probe, and TRUS probe 
corrected (70% threshold), respectively across all three patient volumes. The difference between the 





Figure 3. Effect of threshold level in the source tracking algorithm. The 3D error vector in the presence 
of the TRUS probe is shown in green (k=1). The 3D error vector without the TRUS probe is shown in 
red (k=1). The 3D error vector with different threshold levels applied is shown in blue, pink, and orange, 




Figure 4. Average 3D source tracking error in each catheter considered in the study for patient 1, ± 1 
standard deviation. Red columns show the average error without the TRUS probe. Blue columns show 
the average error with the TRUS probe present and a 70% threshold level applied.  
The results were broken down further to show the average 3D error achieved per catheter 
(Figure 4) for patient 1 only, both without the TRUS probe and with the 70% threshold level applied. 
The catheter numbers increase in the posterior to anterior direction; therefore, the increasing catheter 
number represents an increasing distance between the source and the MP900 array. Typical average 
distances between the source positions in each catheter and the MP900 array ranged from 95 mm to 145 
mm. A trend is observed showing an increased 3D error with increasing average distance between the 




Figure 5. 3D source tracking error in the form of a box-whisker plot for catheter 2 (C2) and catheter 8 
(C8). TRUS probe present and TRUS probe corrected results are presented for each catheter. 
Figure 5 presents a box-whisker plot focusing on catheter 2 and catheter 8 from the patient 1 
plan. Catheter 2 is an example of a catheter which is not shadowed by the TRUS probe as viewed from 
the MP900 array. Catheter 8 is an example where the TRUS probe shadows the primary radiation from 
the Ir-192 source from most detectors in the MP900 array.   
 
IV. DISCUSSION 
The presence of the TRUS probe was found to significantly affect the accuracy of source 
tracking in all three dimensions. Source tracking accuracy without the TRUS probe using the MP900 
was found to be similar, but improved by approximately 0.5 mm, to that found previously using the 
MP121 device [17]. The major discrepancy remains in the z direction (patient anterior-posterior 
direction). The discrepancy in the z direction has been shown previously to be in particular due to the 
non-water equivalence of patient tissue related inhomogeneities between the source and the diode array. 
This was shown by repeating the simulations with each voxel in the geometry assigned a density of 
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water, resulting in a significant improvement in source tracking accuracy [17]. This effect is highlighted 
even more so in Figure 4, where an increased 3D error vector is observed with increasing distance 
between source position and the array, due to the increasing likelihood of the material composition 
between the source and the array being different to that of water.  
The effect of the TRUS probe on source tracking accuracy can be overcome using a 
thresholding technique. An optimal threshold level of 70% of the maximum diode signal was found for 
all source positions in three complete HDR pBT treatment plans. With this threshold of 70%, 
approximately 60% of the detectors in the MP900 are not being used for source position verification 
for the reported example case (patient 1). However, the total number of detectors used in the verification 
algorithm under these conditions is on average equal to 315. This is approximately 2.5 times the total 
number of detectors in the previous version of the device (MP121 array) and justifies the need for the 
MP900 for this purpose. As shown in Figure 3, the 70% threshold level was found to be optimal for all 
three patient geometries, and there was remarkably little variation in source tracking accuracy between 
the three patient geometries. The optimal threshold level may depend more on the TRUS probe design 
and composition, rather than the patient geometry. The effect of the TRUS probe type and design on the 
optimal threshold level will be investigated further in future experimental studies with the MP900. 
Source position detection is in principle impossible, even applying a threshold technique, if the 
source is so close to the probe that its primary radiation oriented towards the array is shielded by the 
probe. Defining a the distance between the centre of the TRUS probe and the array, b the distance 
between the upper surface of the TRUS probe and the source, h the length of the array (i.e.  100 mm for 
the MP121 and 210 mm for the MP900) and d the diameter of the probe (i.e. 22 mm for the Endocavity 





 is valid when the “shadow” of the source matches the lateral edges of the array. In 
Figure 6.b), this equation was used to simulate b depending on both a and the diode array dimensions. 
According to the plot, the use of MP900 allows the reconstruction of the source position even if it is 
over the TRUS probe and close to it, covering all the possible clinical situations. This wouldn’t be 
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possible with the MP121, in particular at increasing distances between TRUS probe and detector array. 








Figure 6.a) Schematic of the setup with the source, TRUS probe and Magic Plate array. a is the distance 
between the centre of the TRUS probe and the array; b is the distance between the external surface of 
the TRUS probe and the source; h is the length of the array; d is the diameter of the probe. Image is not 
to scale; b) Minimum source-probe distance b necessary to avoid the complete shielding of the primary 
radiation of the source that would be detected by the array, plotted at changing array-probe distance a; 
c) TRUS image of the prostate after needle implantation. The closest needle is 10.4 mm over the TRUS 
probe.  
Figure 5 shows on patient 1 an example of a catheter (catheter 2) which is not shadowed by the 
TRUS probe as viewed from the MP900 array and of a catheter (catheter 8) where the TRUS probe 
shadows the primary radiation from the Ir-192 source from most detectors in the MP900 array.  Even 
for catheter 8, which is positioned directly anterior to the TRUS probe, the modified source tracking 
algorithm results in a similar source tracking accuracy to when no probe is present. However, when 
compared to catheter 2, the modified source tracking algorithm applied to catheter 8 results in larger 
discrepancies relative to when there is no probe present. As shown in table 2, there is a higher standard 
deviation of the 3D error results in the TRUS probe corrected group (0.6 mm) compared to the results 
without the TRUS probe (0.3 mm). This is due to the larger uncertainty in correcting for the presence 
of the TRUS probe for catheters that are located directly above the probe where less detectors in the 
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MP900 array can be used for input into the verification algorithm. In general, 3D errors resulted 
significantly higher (p < 0.001) in the TRUS probe corrected group than in the group without TRUS 
probe. Nevertheless, an average source tracking accuracy lower than 2 mm (i.e., 1.8±0.4 mm) can be 
achieved in the clinically relevant condition of the presence of the TRUS probe inside the rectum, after 
application of the TRUS probe correction method.    
The results from this study indicate that the MP900 will have sufficient sensitivity to detect 
errors of approximately 2 mm in the delivery of TRUS based HDR pBT treatments. Such errors may 
include incorrect catheter connection, incorrect source strength, or incorrect reference length entered 
into the BTPS. Errors of this magnitude may also be due to uncertainties in reconstruction of catheters 
on ultrasound images, for example Rylander et al.[10] have shown that errors in catheter reconstruction 
on TRUS images relative to MRI may be up to 9.6 mm. Furthermore, possible needle displacements 
occurring during the treatment planning phase (i.e., post-imaging intra-fraction modifications), which 
might result in changes in the dosimetry of the prostate and OARs [11, 32], could also be detected by 
the use of MP900. 
There still remains, however, a number of significant challenges that must be overcome before 
translating these source tracking simulation studies to routine in-vivo source tracking in clinical practice. 
One example is the poor signal to noise ratio experienced by the detector system at such large source to 
detector distances, when the detector system is placed beneath the patient during HDR pBT. This poor 
signal to noise ratio necessitates the use of longer integration times in the detector system and may 
therefore preclude the system from performing real-time source tracking analysis. This issue has been 
discussed in previous publications on the use of EPID devices for source tracking [13-16]. The Magic 
Plate system, however, is capable of operating with variable integration times between 14 – 9900 μs, 
with a stable sampling frequency between 0.1 – 10 kHz. Previous publications on the application of the 
Magic Plate system to HDR brachytherapy source tracking have demonstrated that real-time analysis is 
possible [18, 19]. Optimisation of detector integration times and sampling frequencies when performing 
source tracking in-vivo will be a focus of future publications.       
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Another challenge that is still to be overcome is the registration of the MP900 to the BTPS 
coordinate system. The accuracy of source tracking can only be as good as the registration between 
these coordinate systems, and previous publications have incorporated stereoscopic imaging [13, 14], 
or electromagnetic tracking [33] in attempts to perform this registration. However, this issue remains 
one of the most significant challenges for accurate localisation of the source position and will also be a 




This study presents a novel methodology for performing source tracking during real-time TRUS 
based HDR pBT. Inclusion of the TRUS probe inside the patient was shown to negatively affect source 
tracking accuracy. However, modification of the source tracking algorithm using thresholding 
techniques was shown to improve source tracking in the presence of the TRUS probe. An optimal 
threshold level of 70% of the maximum diode signal at each source position was determined for all 
source positions in three complete HDR pBT treatment plans, with minor variation observed across the 
three patient volumes. Using this thresholding technique, similar accuracy can be achieved as to when 
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